All In Biotech

Drug Trial Radar · NCT05903274

JSP191 (briquilimab) in Subjects with LR-MDS

A Phase 1 Open-label, Dose-escalation, Safety, and Tolerability Study of JSP191 As a Second-line Therapy in Subjects with Lower-Risk Myelodysplastic Syndrome (LR-MDS)

Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

6

Actual

Start

Jun 19, 2023

Primary completion

Oct 21, 2024

Study completion Oct 21, 2024

Sponsor

Lead sponsor
Jasper Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.

Conditions

  • Lower-risk Myelodysplastic Syndrome

Interventions

  • JSP191Drug

    Subjects will receive intravenous JSP191

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of JSP191Time frame: 32 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Memorial Healthcare System

    Hollywood, Florida

  • Moffitt Cancer Center

    Tampa, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.